“Clinical Responses in Patients With Moderate-to-Severe Plaque Psoriasis Following Withdrawal and Re-Treatment With Risankizumab or Switching from Ustekinumab to Risankizumab”. SKIN The Journal of Cutaneous Medicine, vol. 1, no. 3.1, Oct. 2017, p. s5, https://doi.org/10.25251/skin.1.supp.4.